Diffuse Large B-cell Lymphoma Archives - Page 2 of 10

Lymphoma

Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma

By

Leah Lawrence

September 3, 2021

Response and survival outcomes were similar with rituximab biosimilars and the originator.

A family discusses fertility options with a clinician.

Lymphoma

Treatment Impacts on Fertility for Patients With Hodgkin Lymphoma or Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

August 9, 2021

Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.

Lymphoma

Diffuse B-Cell Lymphoma of CNS After Dimethyl Fumarate Treatment in RRMS

By

Brandon May

August 9, 2021

This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.

Lymphoma

Circulating Tumor DNA May Predict Outcomes of CAR T-Cell Therapy in Large B-Cell Lymphoma

By

Sucharita Mistry, PhD

August 2, 2021

Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.

Patients who received autologous transplant followed by allogeneic transplant experienced improved progression-free survival.

Lymphoma

Low-Cost Transcript-Based Method Developed for Diagnosing Lymphoma Biopsy Samples

By

Vicki Moore, PhD

July 23, 2021

Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.

A doctor explains a medication to an older patient.

Lymphoma

Novel Model Shows High Predictive Potential in Patients With DLBCL

By

Jonathan Goodman, MPhil

July 8, 2021

Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.

Lymphoma

Recommended Dose Determined for Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

June 22, 2021

Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.

Lymphoma

Factors Leading to CAR T Cell Therapy Resistance in Patients With Large B-Cell Lymphoma

By

Vicki Moore, PhD

June 11, 2021

Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.

Lymphoma

Infection-Related Outcomes Relative to R-CHOP Dose in Older Patients With Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

June 10, 2021

This analysis compared infection-related hospitalization and death among patients 70 years of age and older with DLBCL treated with full-dose vs attenuated-dose R-CHOP.